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Abstract 
Resistance and tolerance are two types of host defense mechanisms that increase fitness in 
response to fungi. Several genetic polymorphisms in pattern recognition receptors, most 
remarkably Toll-like receptors (TLRs), have been described to influence resistance and 
tolerance to aspergillosis in distinct clinical settings. TLRs on dendritic cells pivotally 
contribute in determining the balance between immunopathology and protective immunity to 
the fungus. Epithelial cells also contribute to this balance via selected TLRs converging on 
indoleamine-2,3-dioxygenase (IDO). Studies in experimental hematopoietic transplantation 
confirmed the dichotomy of pathways leading to resistance and tolerance to the fungus 
providing new insights on the relative contribution of the hematopoietic/nonhematopoietic 
compartments. 
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Hematopoietic stem cell transplantation (HSCT) has been proven an effective therapeutic 
strategy for hematological malignancies and immune disorders. Despite the significant 
advances witnessed in the technique of transplantation and in therapies to avoid rejection 
episodes, this practice is nonetheless prone to the harmful consequences of the nonspecific 
immunosuppression required for survival of the allograft. In order to minimize these severe 
side effects, research is focusing on the exploitation of therapies leading to tolerance 
induction and immune homeostasis. 
Fungal infections remain nowadays a major cause of transplant-related morbidity and 
mortality in the HSCT setting [1]. One of the most important risk factors for fungal infections 
in HSCT has historically been neutropenia. However, a predominance of aspergillosis cases 
occurring in the post-engraftment rather than the neutropenic period in transplant recipients 
has been described [2]. This suggests that host immunity is crucial in eradicating infection, 
but an overzealous immune recovery can also be harmful and may contribute towards 
worsening disease. Therefore, proper immunotherapies restraining deregulated innate and 
adaptive responses could provide control of immune overreactions in fungal infections [3]. 
In this review, we shall consider the interplay between recipient- and donor-dependent 
mechanisms of protection that are coordinately induced for optimal anti-microbial resistance 
with minimum histopathology (otherwise referred to as protective tolerance). In experimental 
candidiasis and aspergillosis, the balance between Th1 cells (that provide antifungal 
resistance) and regulatory T cells (Tregs) that limit the consequences of the associated 
inflammatory pathology may provide the basis for the occurrence of functionally distinct 
modules of immunity for resistance and tolerance [4]. Specifically, we will discuss the role of 
these protective mechanisms in antifungal immunity and how these can be successfully 
exploited to elicit antimicrobial immunity and concomitant tolerance. Resistance and 
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tolerance are two types of host defense mechanisms that increase fitness in response to fungi 
[4]. 
 
Inflammation and immunity in fungal infections: the current view 
The current understanding of the pathophysiology underlying fungal infection and 
disease fits with the bipolar nature of the inflammatory process in infection [3, 5]. In order to 
achieve the best-fitted form of antifungal resistance, innate responses interplay with adaptive 
immunity, preserving the precarious balance between the opposing effects of inflammation on 
infection. Inflammation is in part required for protection – particularly in mucosal tissues – 
during the transitional response occurring temporally in the bridging between innate and 
adaptive responses. However, uncontrolled inflammation may eventually aggravate disease 
and ultimately oppose pathogen eradication. In this context, taming overzealous and 
exaggerated inflammatory responses has been shown to rely on indoleamine 2,3-dioxygenase 
(IDO), a rate-limiting enzyme in the tryptophan catabolism involved in the inhibition of cell 
proliferation, including that of potentially harmful activated T cells [6], tryptophan catabolites 
and Treg function. In contrast, IL-23 and the Th17 pathway, by down-regulating tryptophan 
catabolism, may instead favor pathology and serve to accommodate the apparently 
paradoxical association of chronic inflammation with fungal persistence [7]. It is of interest 
that the IL-23/Th17 pathway has been recently acknowledged to play an important role in 
transplant rejection and tolerance [8]. In this regard, strategies antagonizing IL-23/IL-17, 
including the administration of synthetic kynurenines, could represent a means of harnessing 
progressive or potentially harmful inflammation [3, 5]. Similarly, we have recently found that 
blocking inflammatory pathways in vivo could also be exploited for the development of 
siRNA therapeutics to attenuate inflammation in aspergillosis [9]. 
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The above findings may assist in explaining the fact that, despite humans being 
constantly exposed to fungi, fungal diseases are relatively rare. This implies that the 
continuous coexistence between fungi and their mammalian hosts plays a underrated 
contribution to the plasticity of the immune system. In fact, recent evidence supports that the 
unremitting integration of pro- and anti-inflammatory signals in response to fungi is critical 
for a proper control of infection and T-cell homeostasis. In this context, IDO and tryptophan 
catabolites are major determinants of this delicate balance, by providing the host with immune 
mechanisms adequate for protection without necessarily eliminating fungal pathogens – 
which would impair immune memory – or causing unacceptable levels of tissue damage [3, 
5]. Ultimately, the mechanism used by the immune system for suppressing autoreactive 
responses could conceivably be employed for therapeutic purposes in transplantation. 
 
Resistance and tolerance to fungi in HSCT 
Dendritic cells provide antifungal immune resistance and tolerance 
Dendritic cells (DCs) orchestrate the adaptive immune responses to Aspergillus [9-10]. 
The plasticity of fungus-pulsed DCs in initiating disparate Th cell responses largely relies 
upon the specialization and cooperation between distinct DC subsets and the discriminative 
recognition of fungal morphotypes by diverse innate recognition receptors [11-13]. For this 
reason, DCs are central in the early decision mechanisms defining immune responses to fungi, 
determining resistance or susceptibility to infection upon the host/fungus interaction. 
Type I IFN-producing plasmacytoid DCs (pDCs) define Th responses and are able to 
induce and sustain protective tolerance, by supporting the generation of Treg with suppressive 
activity [14]. Expansion of pDCs (FL-DCs) is contingent upon the hematopoietic growth 
factor FLT3L and not GM-CSF/IL-4, known to expand conventional, myeloid DCs (GM-
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DCs) [15]. A comparative analysis of murine and human DC subsets for Th priming against 
Aspergillus revealed that FL-DCs, but not the conventional GM-DCs, conferred resistance to 
aspergillosis in experimental HSCT [13]. Interestingly, GM-DCs, although capable of an 
efficient control of fungal growth, were nevertheless associated with inflammatory 
overreactions. These findings highlight the notion that immunotherapy with fungus-pulsed 
DCs may generate both protective and non-protective antifungal responses, corroborating the 
importance of DC plasticity and functional specialization in response to fungi [16]. The 
infusion of selected DC subsets along with donor T cells further enlightens the beneficial or 
detrimental potential of each DC subpopulation in HSCT. In this regard, whereas the infusion 
of GM-DCs greatly accelerated graft-vs.-host-disease (GVHD) onset by T cells, FL-DCs not 
only failed to do so but actually totally prevented it [13]. In fact, FL-DCs were able to control 
inflammation both in infection and GVHD, a feature associated with the concomitant 
activation of IFN-γ+ Th1 cells and FOXP3+IL-10+CD25+ Tregs [13]. 
Vaccination is a potentially important strategy for reducing the risk of infections after 
HSCT. An improved understanding of the pathogen/DC interaction may allow the potential 
use of pathogen- or TLR-conditioned DCs for the induction of patient-tailored Tregs with 
indirect anti-donor allospecificity. In this regard, we have recently found that different cell 
wall components of Aspergillus are endowed with the capacity to activate distinct Th cell 
responses [17]. Most importantly, some fungal antigens retained their immunodominant 
Th1/Treg activating potential across mice and humans, suggesting that the broadness and 
specificity of the human T-cell repertoire against the fungus could be selectively exploited 
with defined immunoactive fungal antigens. 
It has been demonstrated that a division of labor occurs between functionally distinct 
Tregs that are coordinately activated by a CD28/B7-dependent costimulatory pathway after 
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exposure of mice to Aspergillus resting conidia [18]. Inflammation is controlled by the 
expansion, activation and recruitment of CD4+CD25+ Tregs that suppress neutrophils through 
the combined actions of IL-10 and CTLA-4. Late in infection, and similarly in allergy, 
tolerogenic Tregs, which produce IL-10 and TGF-β, inhibit Th2 cells and prevent allergy to 
the fungus. Thus, the capacity of Tregs to inhibit innate and adaptive immunity traits is 
crucial to their regulatory role in fungal infections [13]. Altogether, these findings suggest 
that FL-DCs are fully competent at inducing antifungal resistance and protective tolerance 
upon adoptive transfer in HSCT recipients through the combined action of immunizing and 
tolerizing DCs. In contrast, GM-DCs are capable of immunotoxicity, which may include the 
promotion of inflammation and GVHD. 
 
The nonhematopoietic compartment contributes to protective tolerance to 
Aspergillus 
Airway epithelial cells (ECs) are no longer considered innocent bystanders, being now 
recognized as central participants in innate and adaptive immune responses as well as 
mucosal inflammation and allergy [19]. Through the activation of immune receptors, ECs 
may determine the balance between a state of "mucosal homeostasis", required for optimal 
organ function, and "mucosal injury," leading to mucosal inflammation and barrier 
breakdown. However, recent evidence has also indicated ECs as key players in immunity to 
respiratory pathogens such as Mycobacterium tuberculosis via an IFN-γ/IDO axis culminating 
in the inhibition of Th17 cell responses [20]. 
Airway ECs have been traditionally regarded as reservoirs allowing for the immune 
evasion of the fungus due to the ability of ingested conidia to survive inside them [21]. 
However, recent reports have also established respiratory ECs as key contributors to host 
 7
defense against A. fumigatus [22-24]. It is well established that the proper control of infection 
and associated inflammatory reactions require IDO induction and consequent production of 
tryptophan metabolites with immune-regulatory activities, contributing to the maintenance of 
the Treg/Th17 balance [5, 7]. As clearly shown in susceptible mice, Tregs and Th17-
producing cells mediate antagonizing roles in aspergillosis, where increasing levels of IL-17-
driven inflammation occurred alongside decreased anti-inflammatory Treg responses, 
resulting in inflammatory overreactions [7]. A reciprocal antagonistic relationship was also 
found between IDO and the Th17 pathway, with IDO restraining Th17 responses [5, 25] and 
IL-17A inhibiting IDO [25]. Accordingly, IDO overexpression in airway ECs was found to 
restrain CD4+ T cell activation to the fungus, an activity that was nevertheless dispensable in 
the presence of IDO-expressing tolerogenic DCs [26]. Indeed, in experimental HSCT, IDO-
competent DCs provided protective tolerance to the fungus, by crucially affecting the balance 
between immunity and tolerance in the lung [13]. These data are consistent with the role of IDO 
in hematology, its requirement for the generation of Tregs and for protection against GVHD 
[6]. 
We have recently found that ECs contribute to antifungal immunity by providing protective 
tolerance through a TLR3/TRIF-dependent pathway converging on IDO and may compensate 
for the lack of IDO on hematopoietic cells. [24]. ECs activate IDO via TLR3, that is 
abundantly expressed both intracellularly and on the cell surface of ECs [27], and IFN-γ to 
which ECs also respond. The failure to activate IDO likely accounted for the high levels of 
inflammation seen in Trif-/- mice, as proved by the immunorestorative properties of 
exogenously administered kynurenines, known to induce apoptosis of IL-17A+ γδ+ cells [7]. 
We have shown that exogenous administration of kynurenines restored protective tolerance to 
the fungus [7]. Thus, the therapeutic effects of kynurenines may also encompass IDO 
deficiency in ECs to induce Treg expansion, [19, 28], restrain CD4+ T-cell proliferation [7], 
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and produce IL-10 [24]. As a matter of fact, the highly polarized Th2/Th17 responses seen in 
Trif-/- mice are immunological features compatible with the functional program activated in 
lung DCs by the TRIF pathway [9]. Interestingly, the TLR3 ligand poly(I:C) has also a direct 
costimulatory effect on IFN-γ+ γδ+ cells, a finding suggesting that the protective effect of the 
TLR3/TRIF pathway in infection could be achieved through multiple mechanisms. Overall, 
our data shed light on pathways of immune resistance and tolerance to the fungus that likely 
take place in a hematopoietic transplantation setting. It appears that protective tolerance to the 
fungus is achieved through a TLR3/TRIF-dependent pathway activating Th1/Treg cells via 
IDO expressed on both the hematopoietic/nonhematopoietic compartments. The MyD88 
pathway instead likely provides antifungal resistance, i.e. the ability to restrict the fungal 
growth, likely through defensins and other effector mechanisms. However, the ability of mice 
to clear the fungus in the relative absence of the MyD88 pathway [11, 29], clearly indicates 
redundancies and hierarchy in antifungal mechanisms of resistance. Ultimately, the finding 
that both Candida albicans [30] and A. fumigatus, two major human fungal pathogens, exploit 
the TRIF-dependent pathway at the interface with the mammalian hosts, indicate that the 
combinatorial configuration of antifungal resistance and tolerance is an advantageous option.  
 
Genetic susceptibility to fungal infections in HSCT 
Given the significance of innate immune receptors, namely TLRs, in the eliciting of 
immune responses, it is not surprising that genetic variability of these receptors may affect 
their function and may account, in part, for the inherited differences in susceptibility to 
infection [31] (Table 1). Most genetic studies performed until recently have focused on the 
highly polymorphic TLR4 gene, in which the presence of two co-segregated polymorphisms – 
D299G and T399I – has been found to compromise the ligand-binding properties of TLR4 
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[32]. These polymorphisms have been linked with blunted airway responses to inhaled LPS in 
human individuals and attenuated LPS-induced responses in primary airway ECs. 
One of the first studies establishing a relationship between TLR4 polymorphisms and 
aspergillosis described an increased susceptibility of D299G carriers to a chronic form of 
pulmonary aspergillosis [33]. Shortly thereafter, the same TLR4 polymorphism was also 
found to increase susceptibility to invasive aspergillosis (IA) in HSCT recipients from 
unrelated donors, an observation validated in two different cohorts of patients [34]. 
Interestingly, a previous study, though modest in sample size, had failed to associate the same 
donor polymorphism with IA in HSCT recipients [35]. These apparently discrepant findings 
further highlight the intricacies of genetic associations with infectious complications in the 
transplantation setting, which may ultimately depend on the type of transplant and associated 
clinical variables. In this regard, we have recently described an association between donor 
D299G and colonization by A. fumigatus, but not invasive disease, in a cohort of T-cell-
depleted transplant recipients from related donors [36]. This suggests that, despite its 
prognostic potential, the presence of D299G may not definitely predict the clinical transition 
from fungal colonization to invasive disease, at least in this particular transplant setting. 
Since the abnormal TLR4 ligand-binding domain may be impairing fungal 
recognition, eventually contributing to fungal escape from immune surveillance, individuals 
harboring the D299G polymorphism are likely more prone to develop fungal colonization 
following transplant. However, TLR4 polymorphisms have also been shown to protect from 
hyper-inflammatory diseases, including atherosclerosis and related conditions [37]. Therefore, 
predisposition to fungal colonization may be compensated by the lack on an overreactive 
inflammatory response, which may ultimately condition pathogen elimination. In this regard, 
exaggerated inflammatory responses, more than the fungus itself, may determine 
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susceptibility to aspergillosis and other fungal infections [3]. Thus, and although functional 
studies are ultimately required to confirm this hypothesis, by limiting an exacerbated 
inflammatory response to the fungus, the D299G polymorphism could contribute to resistance 
to aspergillosis, despite evidence of fungal growth. 
Recently, polymorphisms affecting pattern recognition receptors other than TLRs, in 
particular dectin-1, have also been addressed as potential predictive factors for the incidence 
of fungal diseases. Besides associating with recurrent mucocutaneous fungal infections [38], 
the dectin-1 Y238X polymorphism was also found to contribute to increased Candida 
colonization after HSCT [39]. In this context, we have recently found that the Y238X 
polymorphism contributed as well to increased susceptibility to aspergillosis in HSCT [23]. 
Moreover, the genetic association relied on both recipient and donor genetic backgrounds, 
with the highest risk being observed when polymorphic recipient/donor pairs were involved. 
The Y238X polymorphism generates a truncated protein unable to target the membrane and 
mediate β-glucan recognition, therefore resulting in defective cytokine production upon 
receptor engagement [38-39]. Although dectin-1 has been regarded as one major innate 
receptor leading to Th17 activation in response to Aspergillus [40], and the Y238X 
polymorphism was associated with impaired IL-17 production in response to C. albicans or β-
glucan [38], we found that IFN-γ and IL-10, in addition to IL-1β, IL-6 and IL-17A, 
productions by human mononuclear cells carrying the Y238X polymorphism were defective 
upon β-glucan- or Aspergillus-specific stimulation. Thus, these findings point to a previously 
unsuspected role for dectin-1 in antifungal immunity, that is the ability to modulate immunity 
and tolerance via IFN-γ/IL-10 production, both cytokines reflecting the activation of 
protective Th1/Treg antifungal responses. The contribution of recipient dectin-1 deficiency to 
the high risk of infection also reflects the crucial role of dectin-1 expressed on 
nonhematopoietic cells in the induction of immune protection to the fungus, highlighting the 
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distinct, yet complementary, mechanisms of immune resistance and tolerance that are 
dependent on the hematopoietic/nonhematopoietic compartmentalization. 
By influencing immune responses and inflammation, polymorphisms in cytokine 
genes may also help predict post-HSCT complications, including those of infectious nature. In 
this regard, we have recently found that polymorphisms in the IL-23/Th17 pathway may also 
define susceptibility to IA following HSCT [41]. Specifically, donor R381Q in the IL23R 
gene was associated with strong protection from IA, whereas R381Q in patients was 
correlated with improved overall survival [41]. These findings, although requiring replication 
in larger independent data sets, are consistent with the protective effects of IL-23 signaling 
attenuation in experimental aspergillosis [25]. The R381Q polymorphism has already been 
shown to confer protection against GVHD in recipients of grafts from HLA-identical donors 
[42]. Although the genetic findings have been thoroughly replicated, not much is known 
about the functional consequences of this variant. A recent study demonstrated that the 
protective effects displayed by the R381Q polymorphism were due to a deficient activation of 
IL-23-driven Th17 responses [43]. Interestingly, several polymorphisms in the IL17A and 
IL17F genes were not associated with susceptibility to IA in HSCT recipients [41], suggesting 
that additional studies are needed to define cellular and molecular mechanisms by which 
protection from aspergillosis is conferred by the disruption of the IL-23/Th17 axis. 
 
Immunotherapy in HSCT: what does the future hold? 
The new discoveries in the field of fungal immunology have offered new grounds for a 
better comprehension of cells and immune pathways that are amenable to manipulation in 
patients with or at risk of fungal infections, specifically those undergoing HSCT. Therefore, 
devising new strategies to expand and modulate the functions of distinct DC subsets 
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associated with specific regulation of host immunity may provide novel immune-based 
therapies for use in HSCT. One potential difficulty associated with a DC-based treatment 
could be the control of the immunostimulatory/tolerogenic commitment. This could 
eventually be overcome by the targeting of DCs in vivo by biologic or pharmacologic agents. 
In this regard, thymosin-α1 appears to be a suitable candidate to modulate DC functioning for 
active and negative vaccination in transplantation. The therapeutic usage of IDO-mediated 
immune regulation has also been regarded as a promising strategy for use in transplantation. 
As a systemic enhancement of IDO activity by pharmacologic IDO induction would carry the 
risk of inducing general immunosuppression and IDO activity itself is modulated by the 
microenvironment and factors that cannot be controlled in vivo, an alternative therapeutic 
approach as a means of facilitating the generation of tolerance could be the enrichment of 
IDO activity at targeted sites, for example with IDO-competent DCs. In addition to these, 
further understanding of the role of ECs in the maintenance of immune tolerance could also 
be exploited as means of enhancing immunity against fungal pathogens. Specifically, taking 
advantage of the ability of ECs to up-regulate antimicrobial peptides endowed with antifungal 
activity could be regarded as promising target with potential application in the transplantation 
setting. 
Finally, although the dissection of complex genetic traits modulating susceptibility to 
fungal infections is intricate, the contribution of host genetics may hold the key to expose new 
risk factors for these diseases. Therefore, new conceptual advances on the knowledge of host 
immunity need to be accommodated also from an immunogenetic point of view. Identifying 
the cellular and molecular bases affected by genetic polymorphisms may prove a very 
powerful research tool, allowing the identification of potential therapeutic targets and the 
design of prophylactic strategies exerting control over the outcome of immune pathways. The 
genetic screening of at-risk patients may ultimately be used to individualize treatments 
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through the formulation of new targeted and patient-tailored antifungal therapeutics, likely 
improving the management and outcome of fungal infections. 
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Figure legends 
Figure 1. Antifungal resistance and tolerance in hematopoietic transplantation. 
Inflammatory dendritic cells (DCs), with some help from epithelial cells (ECs), provide 
antifungal resistance through the MyD88 pathway that restrains the fungal growth (via 
defensins) and leads to protective Th1/Th17 responses. In contrast, the coordinate action of 
ECs and tolerogenic DCs contribute to fungal tolerance through the TRIF pathway, which 
converges on IDO and expands  Tbet+ Th1 and Foxp3+ Treg cells. 
Table 1. Relevant association studies of polymorphisms in pattern recognition receptors and susceptibility to fungal infections in HSCT 
recipients. 
Gene SNPs Source Event Effect Cases (n) Controls (n) P value Ref. 
TLR1 R80T Recipient IA S 22 105 0.04 [35] 
TLR1/TLR6 N248S/S249P Recipient IA S 22 105 0.02 [35] 
TLR4 D299G/T399I Donor IA S 103 263 0.02 [34] 
TLR4 D299G/T399I Donor Aspergillus colonization S 58 51 0.003 [36] 
TLR4 D299G/T399I Donor IA R 34 24 0.03 † [36] 
DECTIN1 Y238X Recipient Candida colonization S 46 78 <0.001 [39] 
DECTIN1 Y238X Donor and recipient IA S 39 140 0.005 [23] 
 
† Resistance to IA was observed only when comparing IA vs. non-IA among pre-colonized patients with Aspergillus. 
SNP: single nucleotide polymorphism; R: resistance; S: susceptibility; IA: invasive aspergillosis; HSCT: hematopoietic stem cell 
transplantation.
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